Ritter, James, Knox, James, Jan, Darrell, Belancik, Grace, Huang, Roger, Cmarik, Gregory E, Richardson, Tra-My Justine, and Ebner, Armin
International Conference on Environmental Systems; 16-20 Jul. 2017; Charleston, SC; United States
Man/System Technology and Life Support and Chemistry and Materials (General)
In support of air revitalization system sorbent selection for future space missions, Ames Research Center (ARC) has performed CO2 capacity tests on various solid sorbents to complement structural strength tests conducted at Marshall Space Flight Center (MSFC). The materials of interest are: Grace Davison Grade 544 13X, Honeywell UOP APG III, LiLSX VSA-10, BASF 13X, and Grace Davison Grade 522 5A. CO2 capacity was for all sorbent materials using a Micromeritics ASAP 2020 Physisorption Volumetric Analysis machine to produce 0 C, 10 C, 25 C, 50 C, and 75 C isotherms. These data are to be used for modeling data and to provide a basis for continued sorbent research. The volumetric analysis method proved to be effective in generating consistent and repeatable data for the 13X sorbents, but the method needs to be refined to tailor to different sorbents.
Ritter, James, Knox, James, Belancik, Grace, Jan, Darrell, Cmarik, Gregory, Ebner, Armin D, and Huang, Roger
International Conference for Environmental Systems (ICES); 16-20 JUl. 2016; Charleston, SC; United States
Life Sciences (General)
In support of air revitalization system sorbent selection for future space missions, Ames Research Center (ARC) has performed CO2 capacity tests on various sorbents to complement structural strength tests from Marshall Space Flight Center (MSFC). The materials of interest are: Grace Davison Grade 544 13x, Honeywell UOP APG III, VSA-10, BASF 13x, and Grace Davison Grade 522 5A. Each sorbents CO2 capacity was measured using a Micromeritics ASAP 2020 Physisorption Volumetric Analysis machine to produce 0C, 10C, 25C, 50C, and 75C isotherms. These datasets were then extrapolated using Langmuir 3-Site and Toth isotherm models to compare with previously measured capacity data from MSFC using a thermogravimetric analysis approach. The modeling and extrapolation from ARC data correlated well with data measured at MSFC.
This work examined in detail the a priori prediction of the axial dispersion coefficient from available correlations versus obtaining it and also mass transfer information from experimental breakthrough data and the consequences that may arise when doing so based on using a 1-D axially dispersed plug flow model and its associated Danckwerts outlet boundary condition. These consequences mainly included determining the potential for erroneous extraction of the axial dispersion coefficient and/or the LDF mass transfer coefficient from experimental data, especially when non-plug flow conditions prevailed in the bed. Two adsorbent/adsorbate cases were considered, i.e., carbon dioxide and water vapor in zeolite 5A, because they both experimentally exhibited significant non-plug flow behavior, and the water-zeolite 5A system exhibited unusual concentration front sharpening that destroyed the expected constant pattern behavior (CPB) when modeled with the 1-D axially dispersed plug flow model. Overall, this work showed that it was possible to extract accurate mass transfer and dispersion information from experimental breakthrough curves using a 1-D axial dispersed plug flow model when they were measured both inside and outside the bed. To ensure the extracted information was accurate, the inside the bed breakthrough curves and their derivatives from the model were plotted to confirm whether or not the adsorbate/adsorbent system was exhibiting CPB or any concentration front sharpening near the bed exit. Even when concentration front sharpening was occurring with the water-zeolite 5A system, it was still possible to use the experimental inside and outside the bed breakthrough curves to extract fundamental mass transfer and dispersion information from the 1-D axial dispersed plug flow model based on the systematic methodology developed in this work.
Trezza, Christine, Ford, Susan L., Gould, Elizabeth, Lou, Yu, Huang, Chuyun, Ritter, James M., Buchanan, Ann M., Spreen, William, and Patel, Parul
British Journal of Clinical Pharmacology. July 2017, Vol. 83 Issue 7, p1499, 7 p.
Women -- Health aspects, Progesterone, Estradiol, Glycoproteins, Contraceptives, Luteinizing hormone, Contraceptive drugs, and Pituitary hormones
Byline: Christine Trezza, Susan L. Ford, Elizabeth Gould, Yu Lou, Chuyun Huang, James M. Ritter, Ann M. Buchanan, William Spreen, Parul Patel Keywords: cabotegravir; contraceptive; ethinyl oestradiol; levonorgestrel; pharmacokinetics Aims This study aimed to investigate whether cabotegravir (CAB), an integrase inhibitor in development for treatment and prevention of human immunodeficiency virus-1, influences the pharmacokinetics (PK) of a levonorgestrel (LNG) and ethinyl oestradiol (EO)-containing oral contraceptive (OC) in healthy women. Methods In this open-label, fixed-sequence crossover study, healthy female subjects received LNG 0.15 mg/EO 0.03 mg tablet once daily Days 1-10 alone and with oral CAB 30 mg once daily Days 11-21. At the end of each treatment period, subjects underwent predose sampling for concentrations of follicle-stimulating hormone, luteinizing hormone, and progesterone and serial PK sampling for plasma LNG, EO, and CAB concentrations. Results Twenty women were enrolled, and 19 completed the study. One subject was withdrawn due to an adverse event unrelated to study medications. Geometric least squares mean ratios (90% confidence interval) of LNG + CAB vs. LNG alone for LNG area under the plasma concentration-time curve over the dosing interval of duration I and maximum observed plasma concentration were 1.12 (1.07-1.18) and 1.05 (0.96-1.15), respectively. Geometric least squares mean ratio (90% confidence interval) of EO + CAB vs. EO alone for EO area under the plasma concentration-time curve over the dosing interval of duration I and maximum observed plasma concentration were 1.02 (0.97-1.08) and 0.92 (0.83-1.03), respectively. Steady-state CAB PK parameters were comparable to historical values. There was no apparent difference in mean luteinizing hormone, follicle-stimulating hormone, and progesterone concentrations between periods. No clinically significant trends in laboratory values, vital signs, or electrocardiography values were observed. Conclusions Repeat doses of oral CAB had no significant effect on LNG/EO PK or pharmacodynamics, which supports CAB coadministration with LNG/EO OCs in clinical practice.
Clinical Pharmacology in Drug Development; Aug2019, Vol. 8 Issue 6, p790-801, 12p
STAIR climbing, HEPATITIS associated antigen, HEPATITIS B virus, BIOAVAILABILITY, PHARMACOKINETICS, and VIRAL proteins
GSK3389404 is a liver‐targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins. This first‐in‐human, randomized, double‐blind, phase 1 study assessed the safety and pharmacokinetics of GSK3389404 administered subcutaneously (SC) in healthy subjects. Four single ascending‐dose cohorts (10 mg, 30 mg, 60 mg, and 120 mg) and 3 multiple ascending‐dose cohorts (30 mg, 60 mg, and 120 mg once weekly for 4 weeks) each comprised 6 subjects randomized to GSK3389404 and 2 subjects randomized to placebo. There were no serious adverse events (AEs) or withdrawals due to AEs. The safety profile did not worsen with repeated dosing. The most frequent treatment‐related AEs were injection site reactions (19.0% [n = 8/42], frequency unrelated to dose levels); all were mild (Grade 1) and resolved without dose modification or discontinuation. GSK3389404 administered subcutaneously was readily absorbed with a time to maximum plasma concentration (Tmax) of 1–4 hours and an elimination half‐life of 3–6 hours in plasma. Plasma area under the concentration‐time curve (AUC) and maximum observed concentration (Cmax) were dose‐proportional. Dose‐normalized plasma AUC from time 0 to infinity averaged 69.9 ng·h/(mL·mg dose) across cohorts, and Cmax 9.5 ng/(mL·mg dose). Pharmacokinetic profiles and parameters were comparable between single and multiple dosing. No accumulation was observed with once‐weekly dosing. The metabolite was undetectable in urine and plasma. In the pooled urine, GSK3389404 was estimated to account for <0.1% of the total dose. In summary, GSK3389404 dosing has been tested up to 120 mg for 4 weeks with an acceptable safety and pharmacokinetic profile, supporting further clinical investigation in patients with chronic hepatitis B. [ABSTRACT FROM AUTHOR]
Richards, Duncan B., Moon, James C., Fontana, Marianna, Ritter, James M., Lane, Thirusha, Pinzani, Massimo, Barton, Sharon V., Berges, Alienor C., Cookson, Louise M., Gillmore, Julian D., Hawkins, Philip N., and Pepys, Mark B.
The New England Journal of Medicine. Sept 17, 2015, Vol. 373 Issue 12, p1106, 9 p.
Amyloidosis -- Care and treatment and Monoclonal antibodies -- Dosage and administration
The article describes the investigation of whether administration of a single dose of fully humanized monoclonal IgG1 anti- serum amyloid P component (SAP) antibody after (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) infusion would be nontoxic in patients with different types of systemic amyloidosis and would produce a clinically relevant reduction in amyloid load. The results revealed that treatment with CPHPC followed by an anti-SAP antibody led to a reduction in amyloid load from the liver and some other tissues.